Anzeige
Mehr »
Login
Dienstag, 05.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Sagenhafte +10.000 % Gewinnchance mit Spezialisten für KI-Cybersecurity!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C4HE | ISIN: US29415J1060 | Ticker-Symbol: 5HJ
Tradegate
04.11.24
08:00 Uhr
3,140 Euro
+0,020
+0,64 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
ENVVENO MEDICAL CORPORATION Chart 1 Jahr
5-Tage-Chart
ENVVENO MEDICAL CORPORATION 5-Tage-Chart
RealtimeGeldBriefZeit
3,0603,18007:16

Aktuelle News zur ENVVENO MEDICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoenVVeno Medical Corporation: enVVeno Medical Reports Third Quarter 2024 Financial Results and Confirms Guidance for Release of Definitive VenoValve Data in November and Completion of FDA Premarket Approval Application for VenoValve in Q4 of this Year86Continued progress toward submission of 5th and final module of FDA premarket approval (PMA) application for VenoValve® in Q4GLP study for enVVe® transcatheter-based replacement venous valve underway...
► Artikel lesen
28.10.enVVeno Medical Corporation: enVVeno Medical Successfully Initiates 6-Month Pre-Clinical GLP Study Evaluating enVVe124First wave of implants successfully completed with updated delivery system performing very wellCompany on schedule to be in position to apply for approval for enVVe pivotal trial mid-2025 IRVINE, CA...
► Artikel lesen
08.10.NVNO Stock Hits 52-Week Low at $3.06 Amid Market Challenges2
08.10.NVNO-Aktie erreicht 52-Wochen-Tief bei 3,06 US-Dollar1
30.09.enVVeno Medical Corp - 8-K, Current Report2
27.09.NVNO-Aktie erreicht 52-Wochen-Tief bei 3,4 US-Dollar1
27.09.NVNO stock touches 52-week low at $3.4 amid market challenges1
27.09.EnVVeno Medical Announces Pricing Of Public Offering3
27.09.enVVeno Medical stock falls after it prices $15M securities offering1
27.09.enVVeno Medical Corporation Announces Pricing of $15.0 Million Public Offering275IRVINE, CA / ACCESSWIRE / September 26, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today...
► Artikel lesen
26.09.enVVeno Medical launches public stock offering1
26.09.enVVeno Medical startet öffentliches Aktienangebot1
26.09.enVVeno Medical offers to sell common stock2
26.09.enVVeno Medical Corporation Announces Proposed Public Offering192IRVINE, CA / ACCESSWIRE / September 26, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today...
► Artikel lesen
03.09.enVVeno Medical hires VP to lead VenoValve marketing2
03.09.enVVeno Medical Corporation: enVVeno Medical Adds Sandy Prietto to its Executive Team as Vice President of Marketing312MedTech Marketing Leader with Significant New Product Launch Experience for Cardiovascular DevicesKey Addition to Commercial Team as Company Begins Planning for the VenoValve MonetizationSeveral Upcoming...
► Artikel lesen
14.08.enVVeno Medical Corporation: enVVeno Medical Provides Update on FDA Premarket Approval Application Status for VenoValve195VenoValve PMA Approval Application Process Consists of the Submission of 5 Modules to the FDA4 Modules Have Now Been Submitted, Reviewed, and Approved by the FDACompany on Track to File the 5th and...
► Artikel lesen
03.08.enVVeno Medical Corp expected to post a loss of 31 cents a share - Earnings Preview1
01.08.enVVeno Medical reports Q2 results1
01.08.enVVeno Medical Corporation: enVVeno Medical Reports Second Quarter 2024 Financial Results and Provides Corporate Update195- Ended the quarter with $39.1 million cash and investments on hand sufficient to fund operations, through the end of 2025, including potential PMA approval of VenoValve®- Positive interim venous ulcer...
► Artikel lesen
Seite:  Weiter >>
37 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1